Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Inventory (2018 - 2025)

Historic Inventory for Coherus Oncology (CHRS) over the last 8 years, with Q3 2025 value amounting to $2.0 million.

  • Coherus Oncology's Inventory fell 9570.11% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 9570.11%. This contributed to the annual value of $4.2 million for FY2024, which is 9328.01% down from last year.
  • As of Q3 2025, Coherus Oncology's Inventory stood at $2.0 million, which was down 9570.11% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Inventory peaked at $66.8 million during Q3 2023, and registered a low of $2.0 million during Q3 2025.
  • Moreover, its 5-year median value for Inventory was $38.8 million (2022), whereas its average is $38.5 million.
  • In the last 5 years, Coherus Oncology's Inventory skyrocketed by 21402.41% in 2021 and then plummeted by 9570.11% in 2025.
  • Over the past 5 years, Coherus Oncology's Inventory (Quarter) stood at $37.6 million in 2021, then grew by 3.05% to $38.8 million in 2022, then surged by 61.39% to $62.6 million in 2023, then tumbled by 93.28% to $4.2 million in 2024, then crashed by 51.32% to $2.0 million in 2025.
  • Its Inventory stands at $2.0 million for Q3 2025, versus $4.5 million for Q2 2025 and $3.5 million for Q1 2025.